Mechanism of action of N7-methylguanosine in hepatocellular carcinoma

Chun GAO; Jingjing JIANG; Yuchun CHEN; Xiaohui YU; Jiucong ZHANG

doi:10.3969/j.issn.1001-5256.2023.12.029

Volume 39 Issue 12

Dec. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(12): 2946-2951

PDF( 888 KB)

Mechanism of action of N7-methylguanosine in hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2023.12.029

1.
The First Clinical Medical College of Gansu University of Chinese Medicine，Lanzhou 730000，China
2.
Department of Gastroenterology，The 940 Hospital of Joint Logistic Support Force of PLA，Lanzhou 730050，China
3.
Department of Gastroenterology，The Second Hospital of Lanzhou University，Lanzhou 730030，China

Research funding:

Gansu Natural Science Foundation (21JR7RA002);

Gansu Natural Science Foundation (22JR5RA1012);

Central University Excellent Youth Team Cultivation Project (31920220065);

Lanzhou Youth Science and Technology Talent Innovation Key Project (2023-2-29)

More Information

Corresponding author: ZHANG Jiucong， zhangjiucong@163.com （ORCID： 0000-0003-4006-3033）； ZHENG Xiaofeng， zhengxf19892013@126.com （ORCID： 0009-0002-9660-1224）
Received Date: 2023-03-15
Accepted Date: 2023-03-27
Published Date: 2023-12-12

Abstract

Abstract

N7-methylguanosine （m⁷G） is one of the most popular RNA modifications at present and has attracted wide attention from researchers in China and globally. By influencing the metabolism of various RNA molecules （including messenger RNA， ribosomal RNA， microRNA， and transfer RNA）， m⁷G modification actively participates in many biological processes such as cell proliferation， differentiation， and apoptosis. More and more evidence has shown that m⁷G plays a key role in the development of cancer， and abnormal m⁷G levels are closely associated with the development and progression of cancer by regulating the expression of multiple oncogenes and tumor suppressor genes. Hepatocellular carcinoma is the most common gastrointestinal tumor in China， and current treatment methods tend to have an unsatisfactory therapeutic effect. At present， the potential molecular mechanism of m⁷G modification in hepatocellular carcinoma remains unclear. This article reviews the potential mechanism of action of m⁷G modification in hepatocellular carcinoma and the m⁷G-related diagnosis and treatment strategies.
- Carcinoma， Hepatocellular,
- N7-methylguanosine,
- Methylation

FullText(HTML)

References(39)

References

[1]	SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71( 3): 209- 249. DOI: 10.3322/caac.21660.
[2]	GANESAN P, KULIK LM. Hepatocellular carcinoma: New developments[J]. Clin Liver Dis, 2023, 27( 1): 85- 102. DOI: 10.1016/j.cld.2022.08.004.
[3]	REIG M, FORNER A, RIMOLA J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update[J]. J Hepatol, 2022, 76( 3): 681- 693. DOI: 10.1016/j.jhep.2021.11.018.
[4]	THAPAR R, BACOLLA A, OYENIRAN C, et al. RNA modifications: Reversal mechanisms and cancer[J]. Biochemistry, 2019, 58( 5): 312- 329. DOI: 10.1021/acs.biochem.8b00949.
[5]	BARBIERI I, KOUZARIDES T. Role of RNA modifications in cancer[J]. Nat Rev Cancer, 2020, 20( 6): 303- 322. DOI: 10.1038/s41568-020-0253-2.
[6]	FURUICHI Y. Discovery of m(7)G-cap in eukaryotic mRNAs[J]. Proc Jpn Acad Ser B Phys Biol Sci, 2015, 91( 8): 394- 409. DOI: 10.2183/pjab.91.394.
[7]	MALBEC L, ZHANG T, CHEN YS, et al. Dynamic methylome of internal mRNA N⁷-methylguanosine and its regulatory role in translation[J]. Cell Res, 2019, 29( 11): 927- 941. DOI: 10.1038/s41422-019-0230-z.
[8]	MARCHAND V, AYADI L, ERNST FGM, et al. AlkAniline-seq: Profiling of m⁷G and m³C RNA modifications at single nucleotide resolution[J]. Angew Chem Int Ed Engl, 2018, 57( 51): 16785- 16790. DOI: 10.1002/anie.201810946.
[9]	SONG BW, TANG YJ, CHEN KQ, et al. m7GHub: Deciphering the location, regulation and pathogenesis of internal mRNA N7-methylguanosine(m7G) sites in human[J]. Bioinformatics, 2020, 36( 11): 3528- 3536. DOI: 10.1093/bioinformatics/btaa178.
[10]	MA JY, HAN H, HUANG Y, et al. METTL1/WDR4-mediated m⁷G tRNA modifications and m⁷G codon usage promote mRNA translation and lung cancer progression[J]. Mol Ther, 2021, 29( 12): 3422- 3435. DOI: 10.1016/j.ymthe.2021.08.005.
[11]	YING XL, LIU BX, YUAN ZS, et al. METTL1-m⁷ G-EGFR/EFEMP1 axis promotes the bladder cancer development[J]. Clin Transl Med, 2021, 11( 12): e675. DOI: 10.1002/ctm2.675.
[12]	KATSARA O, SCHNEIDER RJ. m⁷G tRNA modification reveals new secrets in the translational regulation of cancer development[J]. Mol Cell, 2021, 81( 16): 3243- 3245. DOI: 10.1016/j.molcel.2021.07.030.
[13]	SUZUKI T. The expanding world of tRNA modifications and their disease relevance[J]. Nat Rev Mol Cell Biol, 2021, 22( 6): 375- 392. DOI: 10.1038/s41580-021-00342-0.
[14]	ALEXANDROV A, MARTZEN MR, PHIZICKY EM. Two proteins that form a complex are required for 7-methylguanosine modification of yeast tRNA[J]. RNA, 2002, 8( 10): 1253- 1266. DOI: 10.1017/s1355838202024019.
[15]	BRAUN DA, SHRIL S, SINHA A, et al. Mutations in WDR4 as a new cause of Galloway-Mowat syndrome[J]. Am J Med Genet A, 2018, 176( 11): 2460- 2465. DOI: 10.1002/ajmg.a.40489.
[16]	SHAHEEN R, ABDEL-SALAM GMH, GUY MP, et al. Mutation in WDR4 impairs tRNA m(7)G46 methylation and causes a distinct form of microcephalic primordial dwarfism[J]. Genome Biol, 2015, 16: 210. DOI: 10.1186/s13059-015-0779-x.
[17]	TRIMOUILLE A, LASSEAUX E, BARAT P, et al. Further delineation of the phenotype caused by biallelic variants in the WDR4 gene[J]. Clin Genet, 2018, 93( 2): 374- 377. DOI: 10.1111/cge.13074.
[18]	MICHAUD J, KUDOH J, BERRY A, et al. Isolation and characterization of a human chromosome 21q22.3 gene(WDR4) and its mouse homologue that code for a WD-repeat protein[J]. Genomics, 2000, 68( 1): 71- 79. DOI: 10.1006/geno.2000.6258.
[19]	BARBIERI I, TZELEPIS K, PANDOLFINI L, et al. Promoter-bound METTL3 maintains myeloid leukaemia by m⁶A-dependent translation control[J]. Nature, 2017, 552( 7683): 126- 131. DOI: 10.1038/nature24678.
[20]	LIU Y, YANG CY, ZHAO Y, et al. Overexpressed methyltransferase-like 1(METTL1) increased chemosensitivity of colon cancer cells to cisplatin by regulating miR-149-3p/S100A4/p53 axis[J]. Aging, 2019, 11( 24): 12328- 12344. DOI: 10.18632/aging.102575.
[21]	OKAMOTO M, FUJIWARA M, HORI M, et al. tRNA modifying enzymes, NSUN₂ and METTL1, determine sensitivity to 5-fluorouracil in HeLa cells[J]. PLoS Genet, 2014, 10( 9): e1004639. DOI: 10.1371/journal.pgen.1004639.
[22]	PANDOLFINI L, BARBIERI I, BANNISTER AJ, et al. METTL1 promotes let-7 microRNA processing via m7G methylation[J]. Mol Cell, 2019, 74( 6): 1278- 1290.e9. DOI: 10.1016/j.molcel.2019.03.040.
[23]	ZHANG LS, LIU C, MA HH, et al. Transcriptome-wide mapping of internal N⁷-methylguanosine methylome in mammalian mRNA[J]. Mol Cell, 2019, 74( 6): 1304- 1316.e8. DOI: 10.1016/j.molcel.2019.03.036.
[24]	ZHAO YC, KONG LQ, PEI ZQ, et al. m7G methyltransferase METTL1 promotes post-ischemic angiogenesis via promoting VEGFA mRNA translation[J]. Front Cell Dev Biol, 2021, 9: 642080. DOI: 10.3389/fcell.2021.642080.
[25]	KADUMURI RV, JANGA SC. Epitranscriptomic code and its alterations in human disease[J]. Trends Mol Med, 2018, 24( 10): 886- 903. DOI: 10.1016/j.molmed.2018.07.010.
[26]	FRAGA MF, URIOL E, BORJA DIEGO L, et al. High-performance capillary electrophoretic method for the quantification of 5-methyl 2′-deoxycytidine in genomic DNA: Application to plant, animal and human cancer tissues[J]. Electrophoresis, 2002, 23( 11): 1677- 1681. DOI: 3.0.CO;2-Z">10.1002/1522-2683(200206)23: 11<1677: AID-ELPS1677>3.0.CO;2-Z.
[27]	SONG LG, JAMES SR, KAZIM L, et al. Specific method for the determination of genomic DNA methylation by liquid chromatography-electrospray ionization tandem mass spectrometry[J]. Anal Chem, 2005, 77( 2): 504- 510. DOI: 10.1021/ac0489420.
[28]	ZHENG GQ, QIN YD, CLARK WC, et al. Efficient and quantitative high-throughput tRNA sequencing[J]. Nat Methods, 2015, 12( 9): 835- 837. DOI: 10.1038/nmeth.3478.
[29]	LI W, LI XY, MA XJ, et al. Mapping the m1A, m5C, m6A and m7G methylation atlas in zebrafish brain under hypoxic conditions by MeRIP-seq[J]. BMC Genomics, 2022, 23( 1): 105. DOI: 10.1186/s12864-022-08350-w.
[30]	LIN SB, LIU Q, LELYVELD VS, et al. Mettl1/Wdr4-mediated m⁷G tRNA methylome is required for normal mRNA translation and embryonic stem cell self-renewal and differentiation[J]. Mol Cell, 2018, 71( 2): 244- 255.e5. DOI: 10.1016/j.molcel.2018.06.001.
[31]	CHIDAMBARANATHAN-REGHUPATY S, FISHER PB, SARKAR D. Hepatocellular carcinoma(HCC): Epidemiology, etiology and molecular classification[J]. Adv Cancer Res, 2021, 149: 1- 61. DOI: 10.1016/bs.acr.2020.10.001.
[32]	CHEN ZH, ZHU WJ, ZHU SH, et al. METTL1 promotes hepatocarcinogenesis via m⁷ G tRNA modification-dependent translation control[J]. Clin Transl Med, 2021, 11( 12): e661. DOI: 10.1002/ctm2.661.
[33]	XIA P, ZHANG H, XU KQ, et al. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB₁ translation in hepatocellular carcinoma[J]. Cell Death Dis, 2021, 12( 7): 691. DOI: 10.1038/s41419-021-03973-5.
[34]	TIAN QH, ZHANG MF, ZENG JS, et al. METTL1 overexpression is correlated with poor prognosis and promotes hepatocellular carcinoma via PTEN[J]. J Mol Med, 2019, 97( 11): 1535- 1545. DOI: 10.1007/s00109-019-01830-9.
[35]	ORELLANA EA, LIU Q, YANKOVA E, et al. METTL1-mediated m⁷G modification of Arg-TCT tRNA drives oncogenic transformation[J]. Mol Cell, 2021, 81( 16): 3323- 3338.e14. DOI: 10.1016/j.molcel.2021.06.031.
[36]	DAI ZH, LIU HN, LIAO JB, et al. N⁷-Methylguanosine tRNA modification enhances oncogenic mRNA translation and promotes intrahepatic cholangiocarcinoma progression[J]. Mol Cell, 2021, 81( 16): 3339- 3355.e8. DOI: 10.1016/j.molcel.2021.07.003.
[37]	HONG ZQ, GOU WX, CUI BQ, et al. Ｒole of the m7G methyltransferase METTL1 in tumours[J]. Chin J Clin Pharmacol Ther, 2023, 28( 1): 93- 100. DOI: 10.12092/j.issn.1009-2501.2023.01.012. 洪子强, 苟文曦, 崔百强, 等. m7G甲基转移酶METTL1在肿瘤中的作用[J]. 中国临床药理学与治疗学, 2023, 28( 1): 93- 100. DOI: 10.12092/j.issn.1009-2501.2023.01.012.
[38]	WANG YT, CHEN J, CHANG CW, et al. Ubiquitination of tumor suppressor PML regulates prometastatic and immunosuppressive tumor microenvironment[J]. J Clin Invest, 2017, 127( 8): 2982- 2997. DOI: 10.1172/JCI89957.
[39]	HUANG ML, LONG JT, YAO ZJ, et al. METTL1-mediated m7G tRNA modification promotes lenvatinib resistance in hepatocellular carcinoma[J]. Cancer Res, 2023, 83( 1): 89- 102. DOI: 10.1158/0008-5472.CAN-22-0963.

Relative Articles

[1]	Huajie XIE, Kai CHANG, Yanyan WANG, Wanlin NA, Huan CAI, Xia LIU, Zhongyong JIANG, Zonghai HU, Yuan LIU. Characteristics of mitochondrial translational initiation factor 2 gene methylation and its association with the development of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2025, 41(2): 284-291. doi: 10.12449/JCH250214
[2]	Xiaomeng YAO, Keke SUN, Yunkai LIN, Hui WANG, Liwei DONG, Lei CHEN, Heping HU. Molecular mechanism of lenvatinib resistance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(12): 2524-2530. doi: 10.12449/JCH241225
[3]	Shichun LU. Challenges and reflections on conversion therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(9): 1738-1740. doi: 10.12449/JCH240904
[4]	Chi MA, Guang TAN. Strategies and practice of conversion therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(9): 1725-1731. doi: 10.12449/JCH240902
[5]	Kaifu LI, Yongcheng TANG, Hao TANG, Xi ZHANG, Benjian GAO, De LUO, Song SU, Bo LI, Xiaoli YANG. Efficacy and safety of three-dimensional visualization technology in assisting ablation therapy for hepatocellular carcinoma： A Meta-analysis[J]. Journal of Clinical Hepatology, 2024, 40(7): 1397-1403. doi: 10.12449/JCH240718
[6]	Liver Oncology Branch, China Association for the Promotion of International Exchange in Healthcare, Immunology Branch. Chinese expert consensus on targeted immunotherapy combined with local therapy for advanced hepatocellular cancer[J]. Journal of Clinical Hepatology, 2023, 39(12): 2782-2792. doi: 10.3969/j.issn.1001-5256.2023.12.006
[7]	Pengwei REN, Ying HAN, Xinmin ZHOU. Predictive indicators for the efficacy of targeted therapy/immunotherapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2705-2709. doi: 10.3969/j.issn.1001-5256.2023.11.028
[8]	Quan ZHOU, Chunlin CAI, Jinqiang LI. Gut-liver axis： Intestinal microbial homeostasis and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2710-2717. doi: 10.3969/j.issn.1001-5256.2023.11.029
[9]	Zhisong NI, Junhan WEN, Weiwei ZHAO, Shoujun YU, Liang HAO, Yu CHENG, Xin LIU. Neoadjuvant therapy for hepatocellular carcinoma： Current situation and prospects[J]. Journal of Clinical Hepatology, 2023, 39(11): 2697-2704. doi: 10.3969/j.issn.1001-5256.2023.11.027
[10]	Ke MA, Lijin ZHAO. Role of N6-methyladenosine in the development and progression of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(9): 2210-2214. doi: 10.3969/j.issn.1001-5256.2021.09.042
[11]	Yanzhen MA, Furong WU, Jiafu ZHANG, Chang FAN, Shaopeng HUANG, Sen CHEN, Hui JIANG. Role of N⁶-methyladenosine methylation in liver diseases[J]. Journal of Clinical Hepatology, 2021, 37(11): 2719-2722. doi: 10.3969/j.issn.1001-5256.2021.11.051
[12]	Zhou Yan, Ning Bo. Application of abnormal cell-free DNA methylation in pancreatic juice in the early diagnosis of pancreatic cancer[J]. Journal of Clinical Hepatology, 2020, 36(9): 2145-2148. doi: 10.3969/j.issn.1001-5256.2020.09.054
[13]	Liu Tao, Xu QiuLing. Spleen-strengthening and dampness-removing therapy exerts a therapeutic effect on nonalcoholic fatty liver disease by regulating hepatic MTP promoter methylation[J]. Journal of Clinical Hepatology, 2019, 35(3): 661-664. doi: 10.3969/j.issn.1001-5256.2019.03.047
[14]	Kang YanHong, Li Wei, Zhan WeiLi, Shang Jia, Yang Lin. Effects of HBV X protein on expression and promoter methylation of p16 tumor suppressor gene[J]. Journal of Clinical Hepatology, 2016, 32(3): 484-487. doi: 10.3969/j.issn.1001-5256.2016.03.017
[16]	Zhang JiCai, Yu ZongTao, Lyu Jun, Li HaiPing, Gao Bo. Relationship between HBV infection and DNMT expression in liver cancer tissues[J]. Journal of Clinical Hepatology, 2013, 29(8): 620-623. doi: 10.3969/j.issn.1001-5256.2013.08.017
[17]	Li HaiPing, Gao Bo, Yu ZongTao, Liu JiuBo, Zhang JiCai. Significance of detection of multigene methylation in liver cancer tissue for early diagnosis of liver cancer[J]. Journal of Clinical Hepatology, 2013, 29(8): 624-626. doi: 10.3969/j.issn.1001-5256.2013.08.018
[18]	Zhang HuiJing, Li ShengMian. Promoter methylation in APC, RASSF1A, WIF-1 gene in digestive system tumors[J]. Journal of Clinical Hepatology, 2011, 27(4): 429-432.
[19]	Xiong QiXiang, Xiong LiJuan. Hepatitis B virus infection and DNA methylation in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2011, 27(8): 881-884.
[20]	Zhang JunXia, Wang Yan, Zhao YanPing, Zhang Bei, Li Jia, Huang Jian. p14ARF promoter methylation and its clinical correlation in primary liver cancer in the population of North China[J]. Journal of Clinical Hepatology, 2011, 27(10): 1051-1054.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(3)

Get Citation

PDF

XML

Article Metrics

Article views (444) PDF downloads(30)

Mechanism of action of N7-methylguanosine in hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2023.12.029

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Mechanism of action of N7-methylguanosine in hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2023.12.029

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content